Kainova Therapeutics, formerly Domain Therapeutics, is a clinical-stage biopharmaceutical company driving a robust pipeline of GPCR-modulating therapies, with a focus on immuno-oncology and inflammation. 

With decades of scientific and medical expertise from its leadership team, Kainova Therapeutics integrates deep biological knowledge with a proprietary, validated, and end-to-end discovery and development approach. This platform enables the company to unlock challenging and underexploited GPCR targets and to advance programs with strong clinical potential. Our track record of collaboration with leading pharmaceutical companies, physicians and global experts, reflects our commitment to rigorous science and strategic partnerships. 

Headquartered in North America with operations in France and Australia, we are advancing our programs with clinical momentum and a focused strategy. Our key programs include, DT-7012, a unique clinical-stage Treg depleting anti-CCR8 antibody with differentiated competitive features and, DT-9046, a first-in-modality biased antagonist of PAR2, complemented by additional programs targeting high-value pathways in immune regulation and inflammatory disease.

As GPCRs re-emerge as next-generation drug targets, Kainova Therapeutics is well positioned to lead the field, combining scientific mastery, operational maturity, and the agility required compete in fast-expanding markets. Our approach centers on advancing differentiated GPCR-modulating therapies and maintaining a pipeline guided by strong scientific rationale. 

At Kainova Therapeutics, we are committed to delivering therapies that create lasting value because we believe that better is always possible.

Kainova Therapeutics

Org chart

Teams

Offices